Status:
TERMINATED
RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Allograft
Post-allograft Relapse
Eligibility:
All Genders
18+ years
Brief Summary
Allogeneic hematopoietic transplantation (AlloHCT) is a robust therapeutic that is used as a consolidation strategy in a number of haematological cancers. It provides durable responses as compared to ...
Detailed Description
For patients with hematological cancers of poor prognosis (acute myeloid leukemia, myelodysplastic syndromes…), proceeding to allogeneic hematopoietic transplantation (AlloHCT) is the definitive curat...
Eligibility Criteria
Inclusion
- Major patient who has been informed about the study;
- Allografted patient with molecular or clinical relapse.
Exclusion
- Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;
- Not able to understand and complete surveys.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 4 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05258929
Start Date
March 1 2022
End Date
June 4 2022
Last Update
March 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055